Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Lilly, UnitedHealth Partner in Study of Bamlanivimab in Covid-19

12/04/2020 | 08:37am EST

By Michael Dabaie

Eli Lilly & Co. and UnitedHealth Group Inc. said they are in a partnership to conduct a study under real-world conditions of bamlanivimab, or LY-CoV555, in high-risk, Covid-19 infected individuals.

The study will treat a large, diverse population of high-risk individuals for Covid-19 with bamlanivimab under real-world conditions with a goal of reducing the severity of illness and hospitalizations, the companies said Friday.

Bamlanivimab recently received emergency use authorization from the U.S. Food and Drug Administration for treatment of mild to moderate Covid-19 patients at high risk for progressing to severe Covid-19 and hospitalization, Lilly said.

The trial will evaluate bamlanivimab versus a control in people that meet the emergency use authorization criteria.

It will draw on both UnitedHealth's UnitedHealthcare health benefits business as well as its Optum health services business to detect and treat high-risk symptomatic patients who test positive for Covid-19, including daily symptom tracking, in-home SARS-CoV-2 testing and in-home infusion services.

"While bamlanivimab is authorized for emergency use based on the efficacy and safety data accumulated to date, larger pragmatic studies in diverse populations can help us further understand the efficacy and safety of SARS-CoV-2 neutralizing antibodies in real world settings," said Daniel Skovronsky, Lilly's chief scientific officer and president of Lilly Research Laboratories.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

12-04-20 0836ET

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 1.87% 206.14 Delayed Quote.22.09%
UNITEDHEALTH GROUP -2.10% 347.55 Delayed Quote.1.23%
All news about ELI LILLY AND COMPANY
01/22ELI LILLY AND : BofA Securities Adjusts Eli Lilly and Company PT to $225 From $1..
MT
01/22ELI LILLY AND COMPANY : - Lilly's neutralizing antibody bamlanivimab prevented C..
AQ
01/21ELI LILLY AND : Says Trial of Monoclonal Antibody Among Nursing Home, Staff Resi..
MT
01/21ELI LILLY AND : Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented..
AQ
01/21ELI LILLY AND : Says Late-Stage Trial Shows Antibody Bamlanivimab Effective in P..
MT
01/21Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds
DJ
01/21ELI LILLY AND : Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented..
PR
01/20ELI LILLY AND : (LLY) Insider Makes Significant Share Sale
MT
01/20ELI LILLY AND : Thinking about trading options or stock in General Motors, Eli L..
PR
01/20FULCRUM THERAPEUTICS : Announces Promotion of Christopher Moxham Ph.D. to Chief ..
AQ
More news
Financials (USD)
Sales 2020 24 415 M - -
Net income 2020 5 821 M - -
Net Debt 2020 11 301 M - -
P/E ratio 2020 32,3x
Yield 2020 1,44%
Capitalization 187 B 187 B -
EV / Sales 2020 8,12x
EV / Sales 2021 7,12x
Nbr of Employees 33 625
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 191,87 $
Last Close Price 206,14 $
Spread / Highest target 10,1%
Spread / Average Target -6,92%
Spread / Lowest Target -41,8%
EPS Revisions
Managers and Directors
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY22.09%183 447
JOHNSON & JOHNSON3.92%425 761
ROCHE HOLDING AG2.51%306 541
NOVARTIS AG2.34%219 658
MERCK & CO., INC.-0.76%205 388
PFIZER INC.-0.71%202 770